Genetics & Genomics

Transgenomic team contributes to study linking stem cell mutation to blood disorder

Published in Blood Weekly, May 18th, 2006

Transgenomic, Inc. (TBIO) announced the publication of a study in which work performed by its Discovery Services team contributed to the finding that patients with a disorder called polycythemia vera (PV) have a mutation in the JAK2 gene in hematopoietic stem cells.

These stem cells represent an early developmental stage in which the blood cells have not yet committed to a specialized function. The JAK2 mutation is likely to be associated with the excessive production of red blood cells in the bone marrow which is characteristic of PV.

Catriona H.M. Jamieson, Moores Cancer Center, University of California, San Diego; key contributing Stanford...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry